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ABSTRACT
Purpose The present study introduces the preparation and in
vitro characterization of a nanoparticle device comprising
holmium acetylacetonate for radioablation of unresectable solid
malignancies.
Methods HoAcAc nanoparticles were prepared by dissolving
holmium acetylacetonate in chloroform, followed by emulsifi-
cation in an aqueous solution of a surfactant and evaporation of
the solvent. The diameter, surface morphology, holmium
content, and zeta potential were measured, and thermal
behavior of the resulting particles was investigated. The stability
of the particles was tested in HEPES buffer. The r2* relaxivity of
protons and mass attenuation coefficient of the nanoparticles
were determined. The particle diameter and surface morphol-
ogy were studied after neutron activation.
Results Spherical particles with a smooth surface and diameter
of 78±10 nm were obtained, and the particles were stable in
buffer. Neutron irradiation did not damage the particles, and
adequate amounts of activity were produced for nuclear
imaging and radioablation of malignancies through intratumoral
injections.
Conclusions The present study demonstrates that HoAcAc
nanoparticleswereprepared usinga solventevaporationprocess.
The particle diameter can easily be adapted and can be optimized
for specific therapeutic applications and tumor types.
KEY WORDS ablation.characterization.holmium.
nanoparticles.tumor
INTRODUCTION
Solid tumors represent the majority of all diagnosed cancer
cases in 2009, accounting for more than 1.3 million new
cases in the USA and approximately 90% of the cancer-
related deaths (1). Treatment options of solid tumors with a
limited number of metastases include surgical resection,
external beam radiotherapy, chemotherapy, and locore-
gional ablation. Surgery is the preferred treatment option,
since this can be regarded as a curative treatment (2). For
patients not amenable for surgical resection, external beam
radiotherapy is often used curatively. However, due to
radiation sensitivity of thea d j a c e n tt i s s u eo rm o t i o n
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In most cases, chemotherapy is applied as palliative
treatment. Percutaneous locoregional thermoablative tech-
niques (e.g. radiofrequency ablation and high intensity
focused ultrasound) are increasingly applied with promising
results in a number of different tumor types, including
tumors in the liver, lungs, and kidneys (2,3). One of the
drawbacks associated with these thermoablative therapies is
the transport of heat from the tumors by blood vessels,
leading to incomplete tumor eradication (3).
The intratumoral administration of beta-emitting radio-
nuclides is an alternative to overcome the drawbacks
associated with thermoablative techniques, whilst retaining
the specificity of local ablation. The intratumoral adminis-
tration of high energy beta-emitting microspheres has been
successfully tested in patients suffering from liver tumors.
Yttrium-90-loaded glass microspheres showed a signifi-
cant tumor response in 24 of 27 patients (4), whereas
phosphorous-32-containing nanocolloids (5)s h o w e da
significant tumor response in 12 of 17 patients. However,
direct visualization of beta particles with a gamma camera
is not possible, making these isotopes unsuitable for
accurate dosimetric calculations. These drawbacks can be
overcome by intratumoral administration of combined beta
and gamma emitters. Holmium-166 (
166Ho) is a very
attractive candidate, since this radionuclide emits gamma
rays in addition to high-energy beta particles, allowing for
both nuclear imaging and radioablation, respectively.
Moreover, holmium can be visualized by CT and MRI
due to its high attenuation coefficient and paramagnetic
properties (6). The intratumoral injection of
166Ho nitrate
(
166Ho(NO3)3) has shown promising results in a rat model
of malignant melanoma. A single injection of holmium
nitrate distributed throughout the tumor, leading to a
significant tumor size reduction (7). A clinically applied
166Ho(NO3)3-loaded device for intratumoral injections is
166Ho(NO3)3-labelled chitosan (8). Response rates were
high in patients with hepatocellular carcinoma (31/40), but
due to leakage of
166Ho to the systemic circulation in more
than 25% of patients (11/40), hematopoietic suppression
was observed. Microspheres with an ultra high holmium
content for intratumoral administration were developed to
o v e r c o m et h e s es i d ee f f e c t s( 9) and were successfully
evaluated in a murine renal cell carcinoma model (10).
Tumor growth was arrested, and no holmium was observed
outside the tumor on SPECT, CT and MRI. Although the
treatment showed promising results, only half of the
intended dose was administered, due to premature settling
of particles in the syringe and the formation of aggregates.
After administration, the microspheres remained at the site
of injection due to their size.
The aim of this study is to develop and characterize a
holmium-containing device that takes advantage of the
favorable properties of micro-sized particles, and circum-
vents their aforementioned downsides. In this paper, we
present the development and characterization of nano-sized
holmium acetylacetonate particles as a potential radio-
ablation device for solid malignancies.
MATERIALS AND METHODS
All chemicals were commercially available and used as
obtained. Acetylacetone, 2,4-pentanedione (AcAc; >99.9%),
chloroform (HPLC-grade), didodecyldimethylammonium
bromide (DMAB; >98%), 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES; >99%), polyvinyl alcohol
(PVA, average MW 30,000–70,000) and sodium hydroxide
(NaOH; 99%) were purchased from Sigma Aldrich (Stein-
heim, Germany). Seakem LE Agarose was purchased from
Lonza (Basel, Switzerland). Holmium (III) chloride hexahy-
drate (HoCl3.6H2O; 99.95%) was purchased from Metall
Rare Earth Ltd. (Shenzhen, China).
Particle Preparation
Holmium acetylacetonate was prepared as described earlier
(11). HoAcAc nanoparticles were prepared by solvent
evaporation after emulsification. HoAcAc crystals were
dissolved in chloroform (5.5% (w/w)) and subsequently
recrystallized by rapid evaporation of the chloroform under
a continuous flow of nitrogen. The recrystallized HoAcAc
was dissolved in chloroform (5.5%, (w/w)), which was
emulsified in an aqueous phase containing a stabilizer
(PVA or DMAB, both 2% w/v) using an Ultra-turrax
homogenizer (Ultra-turrax T25 basic, IKA, Staufen,
Germany) at a stirrer speed of 9,500; 13,500; 20,500;
or 24,000 rpm for 5 min. After emulsification, the organic
solvent was evaporated using a rotator evaporator, and the
nanoparticles were collected by centrifugation (25,000 rpm
for 25 min at 4°C) and washed 6 times with water. The
particles were lyophilized overnight using a Christ “Alpha
1–2” freeze dryer.
Particle Characterization
Nanoparticle diameter was measured by dynamic light
scattering (DLS) using a Malvern ALV CGS-3 (Malvern
Instruments, Malvern, UK) equipped with a JDS Uniphase
22 mW He-Ne laser operating at 632.8 nm at a 90° angle.
Autocorrelation functions were analyzed by the cumulants
method by fitting a single exponential to the correlation
function to obtain the mean size and the PDI, using the
ALV-60×0 software V.3.X provided by Malvern. DLS
results were recorded as the number weighted mean
diameter and Z-average diameter, both in nm.
2206 Bult et al.Scanning electron microscopy (SEM) was performed on
samples that were mounted on an aluminum stub and
coated with a 6 nm layer of platinum. SEM micrographs
were collected on a FEI FEG-SEM XL30 (FEI Company,
Eindhoven, The Netherlands) at a voltage of 5 kV.
Elemental analysis of carbon, hydrogen, oxygen, bro-
mine and holmium of HoAcAc nanoparticles, HoAcAc
crystals, and recrystallized HoAcAc after evaporation of
chloroform was performed by H. Kolbe, Mülheim an der
Ruhr, Germany.
Fourier Transform Infrared Spectroscopy of freeze-dried
HoAcAc nanoparticles, holmium acetylacetonate crystals,
and recrystallized crystals was performed using a Perkin
Elmer SpectrumOne FT-IR spectrometer (PerkinElmer,
Groningen, The Netherlands). The spectra were recorded
using KBr pellets by accumulating 256 scans per spectrum.
A DSC Q1000 (TA instruments Inc., Etten-Leur, The
Netherlands) was used for performing modulated differen-
tial scanning calorimetry. Scans were recorded from 25–
220°C at a heating rate of 2°Cmin
−1 and a modulation
temperature of 1°Cmin
−1.
Zeta potentials of the HoAcAc nanoparticles were
measured using a Zetasizer Nano (Malvern Instruments,
Malvern, UK). Samples of lyophilized nanoparticles were
suspended in 10 mM HEPES at pH 7.4 at a concentration
of 5 mg/ml and sonicated for 10 min; thereafter, the zeta
potential was measured. Reported values are the mean of 3
measurements.
The stability of the HoAcAc particles prepared using
DMABand PVA was studied bydispersing them in a HEPES
buffer at pH 7.4 (10 mM). At different time points (t=0, 1, 2,
4, 8, 24, 48 and 72 h), the particle diameter was measured
using DLS at 25°C, as described before. The release of
holmium from the HoAcAc particles was determined by
transferring 1 ml of a 50 mg/ml suspension of HoAcAc
nanoparticles (either prepared in PVA or DMAB) in 10 mM
HEPES (pH 7.4) to a Slide-a-Lyzer Dialysis Cassette
(Thermo Scientific, Etten-Leur, The Netherlands) with a
10,000 MWCO membrane. All release samples were
prepared in triplicate. The cassettes were dialyzed against
500 ml HEPES buffer (10 mM, pH 7.4). At different
timepoints (t= 0 ,1 ,2 ,4 ,8 ,2 4 ,4 8a n d7 2h ) ,1m lo fs a m p l e
was taken. Four ml HNO3 5% (v/v) were added, and the
holmium content of the resulting solutions was measured
using inductively coupled plasma optical emission spectros-
copy (ICP OES). Samples were measured at three different
wavelengths (339.898, 345.600 and 347.426 nm) in an
Optima 4300 CV (PerkinElmer; Norwalk, USA).
Multimodality Imaging
To determine the sensitivity of MRI and X-ray CT for the
HoAcAc nanoparticles, phantom experiments were carried
out on MRI and CT. The phantom used to determine
MRI and CT sensitivity consisted of agarose (2% (w/w)) gel
samples in which HoAcAc nanoparticles were homoge-
neously dispersed (loadings ranged from 0 to 8 mg nano-
particles per ml agarose) in glass tubes (diameter 10 mm,
length 75 mm). Sample tubes were positioned parallel to
the B0 field in the MR scanner. MR imaging was
performed using a 1.5 and a 3 Tesla clinical MR scanner
(Intera, Achieva, respectively, Philips Healthcare, Best, The
Netherlands). The sensitivity of gradient echo MRI for a
paramagnetic contrast agent can be expressed in terms
of its r2 * relaxivity (in [sec
−1 mg
−1 ml]), which represents
the change in the effective proton transverse relaxation rate
(R2* in [sec
−1]) per unit concentration (in mg/ml). The
R2* relaxation rate characterizes the rate of monoexpo-
nential signal decay due to transverse relaxation. To
determine the r2* relaxivity of HoAcAc particles, the R2*
relaxation rates of the HoAcAc dilution series were
determined with a multiple gradient echo MR sequence,
acquiring 15 echos with an echo spacing of 1.39 msec, a
repetition time of 500 msec, a field of view (FOV) of 128×
128×20 mm, a voxel size of 1×1×5 mm, two signal
averages and a 60° flip angle. Linear regression of the R2*
values and the HoAcAc concentrations provided the r2*
relaxivity (6). For qualitative purposes, a second agarose
phantom was constructed, with depots of HoAcAc nano-
particles in decreasing concentrations by serial dilution
(ranging from 100 μg to 1.5 μg nanoparticles). To obtain
cavities of a reproducible size in this gel, 2 ml pipette tips
were positioned in the gel prior to setting of the gel. After
setting of the gel, the pipette tips were removed, and 50 μl
of a homogeneous HoAcAc nanoparticle suspension was
pipetted into the cavities thus obtained. The particles were
left to settle, followed by filling with agarose gel. This
phantom was positioned coaxially in a 3 Tesla clinical MR
scanner and used to determine the minimal amount of
HoAcAc particles that can be visualized using MR imaging.
Imaging parameters were similar for this phantom setup,
apart from the 15° flip angle.
Quantitative X-ray CT imaging was performed on a
clinical 64 slice CT scanner (Brilliance, Philips Medical
Systems, Best, The Netherlands). The sample tubes were
positioned co-axially to the main axis of the scanner. Using
the methods described by Seevinck et al., a linear regression
curve was constructed to determine the sensitivity of X-ray
CT for HoAcAc nanoparticles (6).
Neutron irradiations were performed in the pneumatic
rabbit system operational in a nuclear research reactor
(Department ofRadiation,Radionuclides and Reactors, Delft
University of Technology, Delft, The Netherlands) (12).
Approximately 50 mg HoAcAc nanoparticles were accurate-
ly weighed and transferred into a high-density polyethylene
vial (Posthumus plastics, Beverwijk, the Netherlands) and
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neutron flux of 5×10
12 nc m
−2s
−1. After neutron
irradiation, the radioactivity was measured. To ensure
safe handling of the nanoparticles for SEM image
acquisition and DLS measurements, the
166HoAcAc
nanoparticles were left to decay for 1 month.
RESULTS AND DISCUSSION
HoAcAc nanoparticles were prepared using solvent evap-
oration technology. In short, recrystallized HoAcAc was
dissolved in chloroform, and the resulting solution was
emulsified in an aqueous solution with 2% (w/w) PVA
followed by evaporation of the solvent. Particles with a
number weighted mean diameter ranging from 1,708±276
to 799±147 nm were obtained when increasing the stirrer
speed from 9,500 to 24,000 rpm (see Table I and Fig. 1).
The yield for all batches was 51±2%. Scanning electron
microscopy (SEM) revealed spherical particles with a
rugged surface (Fig. 1a), with a similar particle diameter
as the number weighted particle diameter observed with
dynamic light scattering (DLS). A larger z-average particle
diameter was measured owing to the presence of a few
large particles (13) (Table I).
To decrease the particle diameter, the cationic surfactant
didodecyldimethylammonium bromide (DMAB) was used
as an emulsifier (14). With increasing stirrer speed from
9,500 to 24,000 rpm, the number weighted mean particle
diameter substantially decreased from 1,168±252 to 78±
10 nm (Table I). The yield for all batches was 47±5%.
Spherical particles with a smooth surface were observed
with SEM (Fig. 1b). The smaller diameter of the particles
using DMAB instead of PVA can be explained by the lower
critical micelle concentration for DMAB compared to PVA
(14). Consequently, DMAB more readily stabilizes chloro-
form droplets in emulsion, promoting the formation of
small chloroform droplets. Particle characterization was
performed on the particles with a mean diameter of around
78 nm prepared with DMAB at a stirrer speed of
24,000 rpm. When PVA particles were used as a
comparison, the particles prepared at 24,000 rpm in PVA
were used.
Table II shows that the holmium content of the HoAcAc
nanoparticles, as determined by elemental analysis, was
43.7% (w/w), which is higher than the holmium content of
the HoAcAc crystals (31.9% (w/w)) used as the starting
material. An increase in holmium content was also
observed in a previous study on the preparation of HoAcAc
microspheres, which was attributed to a loss of acetylacet-
onate during reorganization of acetylacetonate around Ho
(III) ions during the gradual evaporation of the solvent (9).
Interestingly, HoAcAc crystals also showed an increase in
holmium content from 31.9% (w/w) to 38.3% (w/w) after
dissolution of the HoAcAc crystals in chloroform followed
by recrystallization. The holmium content in the HoAcAc
nanoparticles was further increased to 43.7%. The bromine
content was also determined in the HoAcAc nanoparticles
prepared in DMAB, to determine the amount of emulsifier
present after washing. The amount of bromine present was
0.8% (w/w), after washing 6 times with water, which is
representative of 0.8% of DMAB. Infrared spectroscopy,
elemental analysis and differential scanning calorimetry
(DSC) were performed to investigate the HoAcAc nano-
particles and the HoAcAc crystals. The infrared spectra of
the original HoAcAc crystals, recrystallized HoAcAc and
the HoAcAc nanoparticles, irrespective of the preparation
characteristics, show characteristic peaks for acetylaceto-
nate at 1,517 and 1,610 cm
−1 representing the C = C and
the C = O stretching bands of acetylacetonate, respectively
(15) (Fig. 2). This is a confirmation that acetylacetonate is
present in both the recrystallized HoAcAc and the nano-
particles. The presence of small but sharp peaks in the blue
spectrum (HoAcAc crystals) at around 3,600 cm
−1 is an
indication that crystal water is present in the HoAcAc
crystals (16). Thesepeaksarelesspronouncedintheblackand
red spectrum, indicating that the structure of HoAcAc crystals
has changed during particle preparation and water was lost
from the complex. The more pronounced peaks in the red
spectrum (HoAcAc nanoparticles) around 2,800–3,000 cm
−1
Stirrer speed (rpm) Emulsifier Particle diameter Particle diameter PDI
Number weighted mean
a Z-average
a
9,500 2% PVA 1,708±276 2,143±687 0.26
13,500 2% PVA 1,153±259 1,685±29 0.28
20,500 2% PVA 1,002±161 1,414±128 0.24
24,000 2% PVA 799±147 1,175±149 0.25
9,500 2% DMAB 1,168±252 1,677±789 0.25
13,500 2% DMAB 653±166 997±509 0.27
20,500 2% DMAB 311±123 659±68 0.35
24,000 2% DMAB 78±10 462±265 0.21
Table I Effects of Preparation
Variables on the Particle Size and
Polydispersity Index (n=3)o f
HoAcAc Nanoparticles
aresults displayed as particle diame-
ter±standard deviation in nm
PDI Polydispersity Index: a
measure to determine the
heterogeneity of the particle size,
1 being completely heterodis-
perse, 0 being completely
monodisperse.
2208 Bult et al.can be explained by the presence of surfactant in the sample.
These peaks are characteristic for aliphatic alkyl chains
originating from DMAB, the presence of which was
determined by elemental analysis.
Based on results from elemental analysis in combination
with the finding from IR spectroscopy that all forms contain
acetylacetonate, HoAcAc crystals consist of three acetyla-
cetonate ligands and three water molecules complexed with
the Ho(III) ion, as reported previously (16). Elemental
analysis of recrystallized HoAcAc gives evidence that 2.5
acetylacetonate molecules and one water molecule sur-
round each Ho(III) ion, while in HoAcAc nanoparticles
each Ho(III) is expected to be surrounded by two
acetylacetonate molecules and one water molecule (Fig. 3,
Table II).
Differential scanning calorimetry of HoAcAc crystals
showed an endotherm at 126±11°C (Fig. 4a, Table III),
which can be attributed to loss of water from the complex
(15). Interestingly, the thermograms of recrystallized HoA-
cAc show endotherms at 126°C and 156°C (Fig. 4b,
Table III), indicating the presence of a reorganized
HoAcAc structure after recrystallization from chloroform
(Fig. 3). The HoAcAc nanoparticles showed an endotherm
at 198±3°C (Fig. 4c, Table III), likely associated with a loss
of water. The higher temperature needed to expel one water
molecule is an indication that the HoAcAc in the nano-
particles is reorganized in a network-like structure. A
schematic representation of the proposed reorganization
process is shown in Fig. 3. Definite clarification of the
structural rearrangement requires extensive further research.
The use of recrystallized HoAcAc was a prerequisite for
the formation of nanoparticles. When HoAcAc crystals
were used, small needle-like structures were formed instead
of nanoparticles. In HoAcAc crystals, three acetylacetonate
molecules are complexed with one Ho(III) ion. After
recrystallization of HoAcAc, the Ho(III) ion loses half an
acetylacetonate molecule, resulting in one acetylacetonate
molecule that bridges between two Ho(III) ions. When
dissolving the recrystallized HoAcAc in chloroform, followed
by rapid evaporation of the chloroform, another half
acetylacetonate is lost per Ho(III) ion. We expect this to lead
to the formation of another acetylacetonate bridge between
Table II Elemental Analysis of HoAcAc Crystals, Recrystallized HoAcAc and HoAcAc Nanoparticles
HoAcAc crystals (HoAcAc3*3 H2O) HoAcAc recrystallized (Ho2AcAc5*2 H2O) HoAcAc nanoparticles (Ho2AcAc4*H2O)
Calculated (%) Measured
a (%) Proposed (%) Measured (%) Proposed (%) Measured (%)
C 34.9 35.6 34.9 34.1 31.5 31.6
H 5.3 5.3 4.6 4.4 4.2 4.4
O 27.9 26.3 22.3 21.8 21.0 19.9
Ho 31.9 32.6 38.3 37.6 43.3 43.7
Br ––– – <1% 0.8
aMeasured values are presented as the mean of duplicate analyses.
Fig. 1 Scanning electron micrographs of HoAcAc nanoparticles showing the effect of emulsifier on particle diameter and surface a particles prepared using PVA
as emulsifier, b particles prepared using DMAB as emulsifier (stirrer speed was 24,000 rpm for both formulations), c particles prepared using DMAB as
emulsifier after neutron irradiation (1 h at a neutron flux of 5×10
12 nc m
−2s
−1). The magnification was 100,000x for all samples; bar represents 500 nm.
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in this particle preparation method, allowing acetylacetonate
to exert a bridging effect between Ho(III) ions (17).
A positive zeta potential of 26.1±5.4 mV was recorded
for nanoparticles prepared with the cationic surfactant
DMAB. The use of PVA as the stabilizer resulted in
particles with a slightly positive zeta potential value of 3.4±
5.0 mV. The stability of the particles was investigated by
measuring the particle diameter over time. Particles
prepared with DMAB as emulsifier did not show aggrega-
tion after 72 h in 10 mM HEPES buffer pH 7.4, at 25°C.
The positive zeta potential of particles prepared in DMAB
creates repulsive forces between the particles, thereby
preventing particle aggregation (18). Obviously, the zeta
potential of particles prepared in PVA is insufficient to
create these repulsive forces, leading to particle aggrega-
tion. Additionally, the stability of the HoAcAc nano-
particles was investigated by measuring the release of
holmium from the particles after suspension for 72 h in
10 mM HEPES buffer pH 7.4 at 25°C. The release of
holmium from the nanoparticles prepared in DMAB was
1.9±0.1% after 72 h. The release from the particles
prepared in PVA was 7.6±4.7% after 72 h. The particles
prepared in DMAB are more stable and thus seem more
suitable for intratumoral radioablation. However, mid- and
long-term stability experiments in different media (i.e.
serum, lactates, citrates) are required prior to in vivo efficacy
experiments.
The MR imaging characteristics were assessed on
clinical 1.5 and 3 Tesla MR systems using agarose
phantoms with manganese to mimic the susceptibility of
liver tissue (19). The paramagnetic nature of holmium
causes an enhanced transverse relaxation rate, which results
in signal loss seen as blackening on T2* weighted images
(20). The MRI sensitivity of HoAcAc nanoparticles is
described by the r2* and was calculated from transverse
images using the method described by Seevinck et al.( 6).
The r2* is 110 s
−1mg
−1ml (1.5 Tesla) and 295 s
−1mg
−1ml
(3 Tesla), which was lower than expected, when compared
to HoAcAc microspheres (15 μm; r2* 264 s
−1mg
−1ml at 1.5
Tesla (9)) with a similar holmium content (45% w/w). This
lower r2* is likely caused by the particle size of the HoAcAc
nanoparticles. The dephasing of spins for the HoAcAc
microspheres of around 15 μm follows a static regimen
Fig. 2 IR absorbance spectra of HoAcAc crystals (in blue), recrystallized
HoAcAc (in black) and HoAcAc nanoparticles prepared at 24,000 rpm in
DMAB (in red). The spectra were normalized to the peak at 1,517 cm
−1.
Fig. 3 Schematic representation
of the proposed different forms
of HoAcAc complexes. In each
subsequent step, acetylacetonate
and one water molecule is lost.
The remaining acetylacetonate
molecules act as bridges
between Ho(III) ions. (AcAc and
R=acetylacetonate)
Fig. 4 mDSC thermograms of (A) HoAcAc crystals, (B) recrystallized
HoAcAc and (C) HoAcAc nanoparticles. Tmax is the peak maximum of the
endotherm.
2210 Bult et al.where field inhomogeneities caused by holmium are
dephased before molecular diffusion can average out this
signal. In nanoparticle dispersions, however, molecular
diffusion of protons averages out the local field inhomoge-
neities, thereby reducing the r2* of HoAcAc nanoparticles
compared to HoAcAc microspheres (21,22).
An MRI phantom setup was used to determine the
minimum detectable amount of HoAcAc nanoparticles at
3T e s l au s i n gat y p i c a lT 2*w e i g h t e ds c a nt e c h n i q u e
(Fig. 5). The observed minimum detectable amount was
1.5 μg and equals that of HoAcAc microspheres (9), which
is explained by the deposits in which the HoAcAc
nanoparticles are packed together in the phantom mim-
icking larger particles (21,23).
Holmium is a more potent CT contrast agent than the
routinely used iodine-based agents (6). The effect of holmium
on CT is related to its mass attenuation coefficient μ.T h eμ
value was determined by constructing a linear curve as
described by Seevinck et al.( 6). The μ value is 16 HU mg
−1
for the HoAcAc nanoparticles, which is similar to that of
HoAcAc microspheres (9). This was expected, since the μ
valueisnotdependentontheparticlesize,butonlydependent
on the holmium concentration in the phantom (6).
Neither significant changes in the size distribution nor in
particle surface were observed after neutron irradiation of
50 mg HoAcAc nanoparticles (1 h irradiation time and a
neutron flux of 5×10
12 nc m
−2s
−1 (Fig. 1c)) and resulted in
600 MBq of holmium-166. This activity is sufficient for
treatment of a single, solitary, inoperable tumor (<3 cm) by
intratumoral injection (9). Additionally, the gamma rays
emitted by holmium-166 can be visualized by gamma
scintigraphy, the results of which can be used for tumor-
absorbed dose quantification (24).
A limiting factor in intratumoral injection of a micro-
sphere suspension is the aggregation and settling of the
microspheres in the syringe prior to administration. In a
renal cell carcinoma mouse model, this resulted in the
administration of only half of the intended dose of HoAcAc
microspheres (10). According to Stokes’ law, the sedimen-
tation velocity of a particle in a dispersion medium is
proportional to d
2, which is the particle diameter in
centimeter (25). The HoAcAc nanoparticles described in
the present study have an approximately 200-fold lower
diameter compared to the HoAcAc microspheres, which
reduces the sedimentation velocity by a factor 40,000. Also,
the positive zeta potential of the HoAcAc nanoparticles
contributes to prevent aggregation. In this way, a suspension
of HoAcAc nanoparticles prepared in DMAB can be
obtained, which seems ideally suited for intratumoral
injections. In large tumors, multisite injections of micro-
sized holmium particles are required to obtain a homoge-
neous tumor irradiation. In tumors in or near delicate
structures, only single injections can be administered. One
might even speculate that the use of nano-sized particles
results in a homogeneous particle distribution throughout
the tumor, following a single injection, but this is subject of
further investigation.
CONCLUSION
In conclusion, the present study demonstrates that HoAcAc
nanoparticles can be prepared using a solvent evaporation
process. The particle diameter can easily be adapted and
Fig. 5 Agarose MRI phantom setup for the determination of the minimally visible amount of nanoparticles. a) shows how the phantom was constructed,
b) shows a schematic representation of the phantom layout and the amounts of nanoparticles in μg, c) shows the actual image at 3T.
Table III Summary of DSC Results from HoAcAc Crystals, Before and
After Recrystallization, and HoAcAc Nanoparticles (n=4-6)
Onset Tmax (°C) Tmax (°C) ΔH (J/g)
HoAcAc crystals 120±17 126±11 113±12
HoAcAc recrystallized 98±12 112±8 43±9
147±9 154±7 12±5
HoAcAc nanoparticles 187±4 198±3 14±7
Holmium Nanoparticles for Radioablation of Solid Malignancies 2211can be optimized for specific therapeutic applications and
tumor types. The element holmium is very suitable as a
contrast agent, since it is one of the only true multimodality
(radio)nuclides, allowing for MR imaging, CT imaging and
gamma scintigraphy. Moreover, holmium can be made
sufficiently radioactive to exert a therapeutic effect when
injected intratumorally.
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